MODIFIED PTO/SB/08 A & B (06-03)

Substitute for F	orm 1449 A	rm 1449 A & B/PTO			IAP9 RECEPTION 1 6 MAR 20					
Substitute for 1	Substitute for Form 1447 At & Bit 10					Application Number Unknown				
INFORMATION DISCLOSURE						Confirmation Number	Unknown			
STATEMENT BY APPLICANT				CANT		Filing Date	March 16, 2006			
						First Named Inventor	Toshikazu USHIJIMA			
(use as many sheets as necessary)						Art Unit	Unknown			
				•	Examiner Name	Unknown				
Shee	et .	1	of	1		Attorney Docket Number	Q93839			

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document	Number				
		Number	Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
		US					
		US .					
		US					
	•	US					
Î		US					
		US		1	.		

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	For	eign Patent Docur	nent	Publication Date MM-DD-YYYY	Name of Patentee or			
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)		Applicant of Cited Document	Translation ⁶		
						•			
						·			

NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials* No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.				
		M. Jansen et al., "Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade Pan1Ns,", Cancer Biol. Ther., Vol. 1, No. 3, 2002, pages 293-296			
		T. Ueki et al., "Hypermethylation of multiple genes in pancreatic adenocarcinoma", Cancer Res., Vol. 60, No. 7, 2000, pages 1835-1839			
		M. Esteller et al., "A gene hypermethylation profile of human cancer", Cancer Res., Vol. 61, No. 8, 2001, pages 3225-3229			
		B. Gerdes et al., "P16 ^{INK4a} alterations in chronic pancreatitis-indicator for high-risk lesions for pancreatic cancer," <i>Surgery</i> , Vol. 29, No. 4. 2001, pages 490-497			
		H. Zhang et al., "Structure expression of fibrillin-2, a novel microfibrillar component preferentially located in elastic matrices," <i>The Journal of Cell Biology</i> , Vol. 124, No. 5, 1994, pages 855-863			

			*
Examiner Signature	Date Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.